BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, Pourkarim MR, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212-24. [PMID: 32100261 DOI: 10.1007/s12072-020-10015-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
2 Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B; HIDIT-II Study Group. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun 2021. [PMID: 34561972 DOI: 10.1002/hep4.1821] [Reference Citation Analysis]
3 Pourkarim M, Nayebzadeh S, Alavian SM, Hataminasab SH. Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis. Pathogens 2022;11:626. [DOI: 10.3390/pathogens11060626] [Reference Citation Analysis]
4 Pan J, Xu J, Luo H, Tan N, Kang Q, Chen H, Cheng R, Han Y, Yang Y, Xu X. Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy. Int J Infect Dis 2021;105:418-23. [PMID: 33676002 DOI: 10.1016/j.ijid.2021.02.116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang X, Chi X, Wu R, Xu H, Gao X, Yu L, Liu L, Zhang M, Tan Y, Niu J, Jin Q. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4. [PMID: 33407619 DOI: 10.1186/s12985-020-01471-2] [Reference Citation Analysis]
6 Miao M, Clercq E, Li G. Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines 2021;9:412. [PMID: 33920487 DOI: 10.3390/biomedicines9040412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shin S, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. Diagnostics 2022;12:441. [DOI: 10.3390/diagnostics12020441] [Reference Citation Analysis]
8 Wang X, Wang Z, Chi X, Wu R, Jin Q, Xu H, Gao X, Yu L, Chen Y, Shang J, Liu L, Zhang S, Jiang Y, Zhang M, Tong Q, Zhang L, Tan Y, Ma A, Dang S, Xu B, Jin Z, Li J, Li X, Lu F, Niu J. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int J Infect Dis 2020;99:171-8. [PMID: 32721532 DOI: 10.1016/j.ijid.2020.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li G, Xu M, Yue T, Gu W, Tan L. Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochem Pharmacol 2021;185:114485. [PMID: 33617841 DOI: 10.1016/j.bcp.2021.114485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li G, Yue T, Zhang P, Gu W, Gao LJ, Tan L. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecules 2021;26:923. [PMID: 33572409 DOI: 10.3390/molecules26040923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B 2022;12:1567-90. [DOI: 10.1016/j.apsb.2021.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Huang DQ, Khine HTW, Lee C, Tay A, Chan E. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther 2021;53:172-82. [PMID: 33159496 DOI: 10.1111/apt.16149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]